UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Retrieved on:
Monday, June 12, 2023
Other Health, Research, General Health, Pharmaceutical, Optical, Genetics, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Optic neuritis, Multiple Sclerosis Journal, Myelitis, Central nervous system, Attack, University, Glial fibrillary acidic protein, Serum, AC, Multiple sclerosis, University of Virginia School of Medicine, MRI, Virginia School for Girls, Risk, Neuromyelitis optica spectrum disorder, Neuro, Horizon, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry, Medical device, Medical imaging, NMOSD
Properly defining NMOSD attacks is essential to inform treatment decisions, yet there are no universally accepted criteria for accurate and objective diagnosis of NMOSD attacks.
Key Points:
- Properly defining NMOSD attacks is essential to inform treatment decisions, yet there are no universally accepted criteria for accurate and objective diagnosis of NMOSD attacks.
- The N-MOmentum pivotal trial, which demonstrated UPLIZNA reduced the risk of attacks associated with the disease, introduced a new approach for attack analysis.
- Attacks were evaluated by an adjudication committee (AC, comprised of two neurologists and one neuro-ophthalmologist).
- MRI and sGFAP biomarker findings provided additional specificity in the attack adjudication process.